Alterations of the genital mucosal barrier may influence the number of viruses transmitted
from a human immunodeficiency virus–infected source host to the newly infected individual …

Objective: The CAPRISA 004 trial showed that coitally dosed tenofovir 1% gel reduced HIV
acquisition by 39% overall and 54% when used consistently. The objective of this analysis …

The Centre for the AIDS Programme of Research in South Africa 004 (CAPRISA 004) study
demonstrated that vaginally applied tenofovir gel is a promising intervention for protecting …

Background: Women in the CAPRISA 004 trial assigned to use 1% tenofovir (TFV)
microbicide gel, who became HIV-1 infected, had higher viral load set-point and slower …

Background: Although antiretroviral pre-exposure prophylaxis prevents HIV acquisition, it is
not known if it alters HIV disease progression. This study assesses whether tenofovir gel …

Background: Tenofovir gel, an antiretroviral-based vaginal microbicide, reduced HIV
acquisition by 39% in women in a recent randomized controlled clinical trial in South Africa …

Background: Chlamydia trachomatis and Trichomonas vaginalis, two prevalent sexually
transmitted infections, are known to increase HIV risk in women and could potentially …

Tenofovir gel and dapivirine ring provided variable HIV protection in clinical trials, reflecting
poor adherence and possibly biological factors. We hypothesized that vaginal microbiota …

Transmission of drug-resistant HIV has been postulated to be a threat to current first-line
antiretroviral therapy (ART) regimens and the efficacy of several antiretroviral-based …

Recent iPrEx clinical trial results provided evidence that systemic preexposure prophylaxis
(PrEP) with emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) can partially prevent …